ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Grossman Jerrold B

Grossman Adam S

Rosen Law Firm announces securities class action lawsuits against ImmunityBio, Inc. and other companies for allegedly making false and misleading statements. The firm is seeking lead plaintiffs with losses exceeding $100,000 before the May 26, 2026 deadline. According to the lawsuit, ImmunityBio's defendant Patrick Soon-Shiong materially overstated Anktiva's capabilities, resulting in false statements about the company's business and prospects.

IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX

The Rosen Law Firm is investigating potential securities claims against ADMA Biologics (NASDAQ: ADMA) following allegations of channel stuffing to inflate revenue growth. A short seller report by Culper Research triggered a 16.6% stock decline on March 24, 2026. The firm is preparing a class action lawsuit to recover investor losses.

ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

B Group, Inc. initiated a new position in Bright Minds Biosciences by purchasing 67,500 shares worth approximately $5.43 million in Q1 2026. The investment signals confidence in the company's epilepsy drug pipeline, particularly BMB-101. Bright Minds is a pre-clinical biotech firm with a well-funded balance sheet (C$309.7 million in cash) and no commercial revenue, representing a high-risk, high-reward opportunity for long-term investors.

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline

B Group increased its position in ADMA Biologics by 750,000 shares ($11.84 million) in Q1 2026, bringing its total stake to 3.2 million shares worth $28.90 million (21.4% of AUM). Despite ADMA shares falling 58% over the past year, the fund's confidence appears justified by Q1 results showing flat revenue but 22% growth in adjusted net income and 24% EBITDA growth, driven by strong 28% year-over-year growth in ASCENIV sales.

Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year

The Rosen Law Firm is investigating potential securities claims against ADMA Biologics (NASDAQ: ADMA) following allegations of channel stuffing to inflate revenue. A short seller report by Culper Research triggered a 16.6% stock decline on March 24, 2026. The firm is preparing a class action lawsuit to recover investor losses.

ADMA Biologics Inc (ADMA) Stock Price, Analysis & Trade Signals